文献速递免疫规划传染病防控与疫情报告

美国现役军人接种伤寒沙门菌疫苗的情况

Vaccination of active component US military personnel against Salmonella Typhi.
PubMed 文献 · Vaccine · 2017-03-06

该研究利用国防医疗监测系统数据,描述1998至2011年美国现役军人接种伤寒沙门菌疫苗的使用情况及急性反应原性。Vi疫苗后恶心、头痛、发热报告率显著高于Vivotif,而Vivotif后皮疹和非感染性腹泻报告率较高。

要点

  • Vi疫苗后恶心195/10万、头痛13/10万、发热40/10万,显著高于Vivotif的130、2、10/10万。
  • Vivotif后皮疹186/10万和非感染性腹泻426/10万,高于Vi疫苗。

核心结论

  • 美国军队是伤寒沙门菌疫苗的主要使用群体,胃肠外接种的Vi疫苗似乎更易被接受,但作者评估其使用率较高原因的能力有限。
  • 虽然观察到接受肌内接种疫苗的受试者中几种不良事件发生率较高,但这些事件的总体发生率较低。
  • 作者认为有必要开展评估更长期健康结局的未来研究。

研究设计与样本

  • 数据来自国防医疗监测系统,通过疫苗接种代码识别1998年至2011年间的接种记录。
  • 评估接种后四周内的临床结局,并估算两种疫苗类型的不良事件发生率和比值比。

主要发现

  • 在伤寒沙门菌疫苗接种前后6个月内接种其他疫苗的情况常见。
  • Vi荚膜多糖疫苗后恶心(每10万剂次195)、头痛(每10万剂次13)和发热(每10万剂次40)的发生率显著高于接种Vivotif(分别为每10万剂次130、2、10)。
  • 接受Vivotif者皮疹(每10万剂次186)和非感染性腹泻(每10万剂次426)的发生率高于Vi荚膜多糖疫苗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者评估Vi疫苗使用率较高原因的能力有限。
  • 作者认为有必要开展评估更长期健康结局的未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vaccination against Salmonella Typhi is one of the leading public health interventions reducing the risk of typhoid fever. There are two available licensed vaccines, Vivotif, oral live-attenuated, and Typhim Vi, intramuscular Vi capsular polysaccharide. The US military is a high risk travel population commonly vaccinated for S. Typhi. We describe the use of S. Typhi vaccination in this population and the acute reactogenicity profile of these vaccines. METHODS: Data were obtained from the Defense Medical Surveillance System and vaccination identified between 1998 and 2011 from vaccination codes. Clinical outcomes were assessed for four weeks post vaccination. Adverse event rates and odds ratios were estimated across the two vaccine types. RESULTS: A total of 1.9million predominately male military personnel received 3.6 million S. Typhi vaccinations with 94.3% of vaccinees receiving the Vi capsule vaccine though variability in the vaccine administered was observed. Receipt of other vaccinations in the 6months surrounding the S. Typhi vaccine was common. Rates of nausea (195 per 100,000 vaccinations), headache (13 per 100,000 vaccinations) and fever (40 per 100,000 vaccinations) were significantly higher following Vi capsule vaccination compared to receipt of Vivotif (130, 2, 10 per 100,000 vaccinations, respectively). In contrast the rates of rash and non-infectious diarrhea (186 and 426 per 100,000 vaccinations, respectively) were increased in those receiving Vivotif compared to the Vi capsule vaccine. DISCUSSION: The US military is a major consumer of S. Typhi vaccines. The parenterally administered vaccine appears to be more amenable, though we were limited in our ability to assess the reasons for its higher usage. While we observed a higher rate of several adverse events in subjects receiving the intramuscular vaccination, the overall rate of these events was low. Future studies assessing more long-term health outcomes are warranted.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Porter CK, Sorrell T, Mitra I, et al. Vaccination of active component US military personnel against Salmonella Typhi. Vaccine. 2017. PMID: 28268075. doi:10.1016/j.vaccine.2017.02.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。